Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gary Cutter

Showing results (221-230 of 333) with videos related to

Pageof 34
Sort By:
Multiple Sclerosis and Related Disorders|February 7, 2020
Satisfaction and adherence with glatiramer acetate 40mg/mL TIW in RRMS after 12 months, and the effect of switching from 20mg/mL QDGary Cutter, Antonella Veneziano, Augusto Grinspan, et al.
The New England Journal of Medicine|February 14, 2024
Inhibition of CD40L with Frexalimab in Multiple SclerosisPatrick Vermersch, Cristina Granziera, Yang Mao-Draayer, et al.
Contemporary Clinical Trials|April 26, 2019
Rationale and design of the STEP for MS Trial: Comparative effectiveness of Supervised versus Telerehabilitation Exercise Programs for Multiple SclerosisRobert W Motl, Deborah Backus, Whitney N Neal, et al.
Multiple Sclerosis and Related Disorders|May 28, 2019
Higher satisfaction and adherence with glatiramer acetate 40 mg/mL TIW vs 20 mg/mL QD in RRMSGary Cutter, Antonella Veneziano, Augusto Grinspan, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|May 12, 2012
A genetic variant of the anti-apoptotic protein Akt predicts natalizumab-induced lymphocytosis and post-natalizumab multiple sclerosis reactivationSilvia Rossi, Caterina Motta, Valeria Studer, et al.
Hypertension (Dallas, Tex. : 1979)|December 13, 2017
Accuracy of Blood Pressure Measurement Devices in Pregnancy: A Systematic Review of Validation StudiesNatalie A Bello, Jonathan J Woolley, Kirsten Lawrence Cleary, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|September 1, 2025
Comparing the macromolecular-to-free pool size ratio and the magnetization transfer ratio for the assessment of myelin injury in early multiple sclerosisAhmad A Toubasi, Marc Graham, Gary Cutter, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|October 13, 2023
Relapse recovery in relapsing-remitting multiple sclerosis: An analysis of the CombiRx datasetMarcus W Koch, Ester Moral, Luis Brieva, et al.
Multiple Sclerosis and Related Disorders|March 8, 2022
Measuring cognitive function by the SDMT across functional domains: Useful but not sufficientJustin M Leach, Gary Cutter, Daniel Golan, et al.
Multiple Sclerosis Journal - Experimental, Translational and Clinical|May 4, 2023
Serum neurofilament light-chain levels and long-term treatment outcomes in relapsing-remitting multiple sclerosis patients: A post hoc analysis of the randomized CombiRx trialGary Cutter, Richard A Rudick, Carl de Moor, et al.
Pageof 34

Showing results (221-230 of 333) with videos related to

Sort By:
Pageof 34
Multiple Sclerosis and Related Disorders|February 7, 2020
Satisfaction and adherence with glatiramer acetate 40mg/mL TIW in RRMS after 12 months, and the effect of switching from 20mg/mL QDGary Cutter, Antonella Veneziano, Augusto Grinspan, et al.
The New England Journal of Medicine|February 14, 2024
Inhibition of CD40L with Frexalimab in Multiple SclerosisPatrick Vermersch, Cristina Granziera, Yang Mao-Draayer, et al.
Contemporary Clinical Trials|April 26, 2019
Rationale and design of the STEP for MS Trial: Comparative effectiveness of Supervised versus Telerehabilitation Exercise Programs for Multiple SclerosisRobert W Motl, Deborah Backus, Whitney N Neal, et al.
Multiple Sclerosis and Related Disorders|May 28, 2019
Higher satisfaction and adherence with glatiramer acetate 40 mg/mL TIW vs 20 mg/mL QD in RRMSGary Cutter, Antonella Veneziano, Augusto Grinspan, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|May 12, 2012
A genetic variant of the anti-apoptotic protein Akt predicts natalizumab-induced lymphocytosis and post-natalizumab multiple sclerosis reactivationSilvia Rossi, Caterina Motta, Valeria Studer, et al.
Hypertension (Dallas, Tex. : 1979)|December 13, 2017
Accuracy of Blood Pressure Measurement Devices in Pregnancy: A Systematic Review of Validation StudiesNatalie A Bello, Jonathan J Woolley, Kirsten Lawrence Cleary, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|September 1, 2025
Comparing the macromolecular-to-free pool size ratio and the magnetization transfer ratio for the assessment of myelin injury in early multiple sclerosisAhmad A Toubasi, Marc Graham, Gary Cutter, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|October 13, 2023
Relapse recovery in relapsing-remitting multiple sclerosis: An analysis of the CombiRx datasetMarcus W Koch, Ester Moral, Luis Brieva, et al.
Multiple Sclerosis and Related Disorders|March 8, 2022
Measuring cognitive function by the SDMT across functional domains: Useful but not sufficientJustin M Leach, Gary Cutter, Daniel Golan, et al.
Multiple Sclerosis Journal - Experimental, Translational and Clinical|May 4, 2023
Serum neurofilament light-chain levels and long-term treatment outcomes in relapsing-remitting multiple sclerosis patients: A post hoc analysis of the randomized CombiRx trialGary Cutter, Richard A Rudick, Carl de Moor, et al.
Pageof 34